Scioderm, led by CEO Robert Ryan, Ph.D., is a Durham, North Carolina-based clinical-stage pharmaceutical company focused on developing therapies for diseases with critical unmet medical needs, including orphan indications. Its lead product is Zorblisa (SD-101), a proprietary topical therapy being developed for all patients with Epidermolysis Bullosa (EB). The company intends to use the Series B proceeds to fund Zorblisa through completion of U.S. and EU clinical registration programs. Scioderm planned to initiate the clinical trial in the first quarter of 2015 and expected to report top-line results in the second half of 2015. The company emphasizes development of orphan products and advancing its clinical registration strategy. The financing improves Scioderm's near-term runway to execute those planned registration trials. Scioderm is a Raleigh, NC-based clinical-stage pharmaceutical company led by Robert Ryan, Ph.D., CEO and co-founder. The company focuses on developing topical products to address critical medical needs in the treatment of chronic skin diseases. Its lead program is SD-101, a topical cream intended to treat the skin effects seen in patients across all epidermolysis bullosa (EB) subtypes. Scioderm plans to use the new funding to advance SD-101 into clinical development through registration. The company completed a $16M Series A financing to support those plans. As part of the financing, two partners from the lead investors joined Scioderm’s board of directors.

Total raised

$36M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2014